This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.81% per year. These returns cover a period from January 1, 1988 through September 1, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Mylan (MYL) to Report Q2 Earnings: Is a Beat in the Cards?
by Zacks Equity Research
Investors will look forward to regular top and bottom-line numbers and updates on the merger with Upjohn, when Mylan (MYL) reports Q2 results.
What's in the Cards for Regeneron's (REGN) Q2 Earnings?
by Zacks Equity Research
Investors will focus on the performance of Eylea and Dupixent along with other pipeline updates when Regeneron (REGN) reports second-quarter 2020 results.
How Much Will Coronavirus Hurt Merck's (MRK) Q2 Earnings? (Revised)
by Zacks Equity Research
Investor focus is likely to be on the impact of the coronavirus outbreak on Merck's(MRK) performance when it reports second-quarter earnings.
Vaxart (VXRT) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Vaxart (VXRT) has been actively engaged in developing a coronavirus vaccine. Investors are likely to focus on progress of vaccine program on the Q2 earnings call.
Incyte (INCY) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Incyte (INCY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is a Beat in the Cards for Incyte's (INCY) Q2 Earnings?
by Zacks Equity Research
Investors will focus on regular top and bottom-line numbers along with pipeline updates, when Incyte (INCY) reports second-quarter 2020 results.
Moderna (MRNA) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Investors focus is likely to be on the progress of its pipeline candidates, especially coronavirus vaccine candidate, on the second-quarter earrings call.
How Much Will Coronavirus Hurt Merck's (MRK) Q2 Earnings?
by Zacks Equity Research
Investor focus is likely to be on the impact of the coronavirus outbreak on Merck's (MRK) performance when it reports second-quarter earnings.
Sanofi (SNY) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Investor focus is likely to be on the impact of the coronavirus outbreak on Sanofi's (SNY) performance when it reports second-quarter results.
What's in Store for Novavax (NVAX) This Earnings Season?
by Zacks Equity Research
Novavax (NVAX) is developing a coronavirus vaccine. The company is likely to provide an update on the vaccine's progress on its Q2 earnings call.
How Hard Will Coronavirus Hit Lilly's (LLY) Q2 Earnings?
by Zacks Equity Research
Investor focus is likely to be on the extent of the impact of the coronavirus outbreak on Lilly's (LLY) performance when it reports second-quarter earnings.
Is a Beat in Store for Dynavax (DVAX) This Earnings Season?
by Zacks Equity Research
Dynavax (DVAX) is actively pursuing development of coronavirus vaccine through collaborations. Investors are likely to focus on progress of vaccine programs on Q2 earnings call.
How Damaging Will Coronavirus be for AbbVie (ABBV) Q2 Earnings?
by Zacks Equity Research
Investor focus is likely to be on the impact of the coronavirus outbreak on AbbVie's (ABBV) performance when it reports second-quarter results.
What's in Store for CRISPR (CRSP) This Earnings Season?
by Zacks Equity Research
CRISPR Therapeutics (CRSP) is developing its lead gene-editing candidate for thalassemia and sickle cell disease. The company is expected to provide an update on its progress on the earnings call.
What's in the Cards for Glaxo (GSK) This Earnings Season?
by Zacks Equity Research
Glaxo's (GSK) Vaccines and Respiratory segments are likely to have driven second-quarter sales. Results will provide clarity on the impact of coronavirus on the company's business.
Amgen (AMGN) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Investor focus is likely to be on the extent of the impact of the coronavirus outbreak on Amgen's (AMGN) performance when it reports second-quarter results.
What's in Store for AstraZeneca (AZN) This Earnings Season?
by Zacks Equity Research
AstraZeneca's (AZN) second-quarter results are expected to reflect the impact of new drug sales. However, the impact of coronavirus pandemic remains to be seen.
Biotech Stock Roundup: BIIB Reports Q2, GILD Acquires Stake in Private Company & More
by Zacks Equity Research
The biotech sector remains in focus with earnings, regulatory and other pipeline updates.
Novartis' (NVS) Q2 Earnings Surpass Estimates, Sales Miss
by Zacks Equity Research
Novartis' (NVS) second-quarter 2020 sales take a hit due to the coronavirus pandemic.
Equillium Gains From Positive Results on Coronavirus Drug
by Zacks Equity Research
Equillium (EQ) soars on positive results on pipeline candidate, itolizumab, for COVID-19.
Gilead Prices Coronavirus Drug Remdesivir at $390 Per Vial
by Zacks Equity Research
Gilead (GILD) prices experimental coronavirus drug, remdesivir, at $390 per vial.
Bristol Myers & Acceleron Obtain EC Approval for Reblozyl
by Zacks Equity Research
Bristol Myers (BMY) and partner Acceleron win EC approval of Reblozyl (luspatercept) for two indications.
Gilead's (GILD) Remdesivir Gets CHMP Approval Recommendation
by Zacks Equity Research
Gilead's (GILD) experimental coronavirus drug, remdesivir, has been recommended for approval by the EMA's human medicines committee.
Alexion's (ALXN) SC Ultomiris Meets Primary Goal in Phase III
by Zacks Equity Research
Alexion's (ALXN) subcutaneous formulation of Ultomiris meets primary objective in a late-stage study.
Merck's Keytruda Wins FDA Nod for Squamous Cell Skin Cancer
by Zacks Equity Research
Merck's (MRK) sBLA for Keytruda for recurrent or metastatic cutaneous squamous cell carcinoma, a form of skin cancer, gets approval from the FDA.